Remington-Davis, Inc | Columbus, OH
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study will last approximately 2 years may include up to 27 visits.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Have been diagnosed with type 2 diabetes mellitus (T2DM)
Are at least 18 years of age or legal age of consent in the jurisdiction in which the study is taking place, whichever is older.
Have HbA1c at screening
Are on stable treatment of at least 1 and no more than 3 oral antihyperglycemic drugs for at least 90 days before screening. Antihyperglycemic drugs may include metformin, SGLT-2 inhibitors, and/or sulfonylureas
Have increased risk for cardiovascular (CV) events due to:
Are of stable weight (± 5%) for at least 90 days prior to screening
Have a BMI ≥25 kilograms per meter squared (kg/m2) at screening
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
2,620 participants in 2 patient groups
Loading...
Central trial contact
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal